Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

S&P Biotech SPDR (NY: XBI )

89.97 +1.63 (+1.85%)
Streaming Delayed Price Updated: 1:07 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about S&P Biotech SPDR

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
How Are Biotech ETFs Reacting To These Q3 Earnings Releases?
There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see... 
Via Talk Markets
Wednesdays With Wedbush On PreMarket Prep Plus
On the PreMarket Prep Plus "Wednesday’s With Wedbush" segment, Sahak Manuelian, managing director and head of equi... 
Via Benzinga
15 Charts All Traders Should Look At Every Morning
One of the hardest things to do as a day trader is gathering all the necessary information to execute profitable trades. Below are the to... 
Via Benzinga
Look For The Q4 Biotech Bounce In Mid-Small Caps
Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best... 
Via Talk Markets
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity
SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) shares... 
Via Benzinga
Topics Stocks
Exposures US Equities
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity
SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) shares... 
Via Benzinga
Topics Stocks
Exposures US Equities
Unusual Options Activity Insight: SPDR Series Trust SPDR S&P Biotech ETF
On Friday, shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE: 
Via Benzinga
Topics Stocks
Exposures US Equities
Understanding SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity
Shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI 
Via Benzinga
Topics Stocks
Exposures US Equities
Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day. 
Via Talk Markets
Healthcare Stocks Hit New Highs but Small Caps Lag
Many smaller cap biotech stocks trade on news and milestones and have no earnings so require more expertise in the field. 
Via Talk Markets
ETF Reflections: US Stocks
I'm a bear. So the longer they prop this dreck up, the greater the fall. Suits me! 
Via Talk Markets
Biotech ETFs To Benefit From Latest Booster Update
Vaccine makers like Moderna and Pfizer have reasons to cheer the update with regard to the application of boosters. The U.S. government announced plans to make COVID-19 vaccine boosters available from... 
Via Talk Markets
Exposures COVID-19
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity
On Monday, shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) saw unusual options activity. After the option alert, the stock price moved down to $122.44. Sentiment... 
Via Benzinga
Topics Stocks
Exposures US Equities
Unusual Options Activity Insight: SPDR Series Trust SPDR S&P Biotech ETF
SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) shares... 
Via Benzinga
Topics Stocks
Exposures US Equities
Large Cap Biopharma Stocks provide Growth and Value
The S&P 500 Healthcare Index was up 0.53% and biotech still lags in healthcare yet Large Cap Biopharma is doing well YTD. 
Via Talk Markets
Topics Stocks
Exposures US Equities
ETF Investing Areas to Consider for August
There is no doubt that the second-quarter 2021 earnings season is going strong. 
Via Talk Markets
Carter Worth And Mike Khouw's XBI Trade
On CNBC's "Options Action," Carter Worth of Cornerstone Macro said SPDR S&P Biotech ETF (NYSE: XBI) has a bounce potential, having sold off to support. XBI is an... 
Via Benzinga
Topics Stocks
Exposures US Equities
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity Shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE: XBI) saw some unusual options activity... 
Via Benzinga
Topics Stocks
Exposures US Equities
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity
On Thursday, shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) saw unusual options activity. After the option alert, the stock price moved up to $126.24. Sentiment... 
Via Benzinga
Topics Stocks
Exposures US Equities
Understanding SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity
Shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved down to $132... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mid-Cap Biotech Picks: Seasonal Rally Underway
Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable. 
Via Talk Markets
IBB Vs. XBI: Which Biotech ETF Has A Better Chart?
The SPDR S&P Biotech ETF XBI is trading below an important resistance level, but the iShares Nasdaq Biotechnology ETF IBB has broken out. 
Via Talk Markets
Topics Stocks
Exposures US Equities
IBB Vs. XBI: Which Biotech ETF Has A Better Chart?
The SPDR S&P Biotech ETF (NYSE: XBI) is trading below an important resistance level, but the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) has broken out. Resistance is a... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated
Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) robust ... 
Via Benzinga
Healthcare Portfolio Playbook: Time To Rebalance With MedTech
As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap... 
Via Talk Markets
Should You Buy Biotech ETFs Now?
Instead of trying to pick winners in this volatile space, it is better to invest in broader biotech ETFs that stand to benefit from increased investor interest and rising spending on drugs and... 
Via Talk Markets
Tuesday Talk: Action!
U.S. stock markets started the week in continued action mode. The S&P 500 closed at 4,255, up nearly 8 points, the Dow closed at 34,394, down 85 points and the Nasdaq Composite closed at 14,174, up... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Biotechs Ready To Roar
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
Exposures Product Safety
3 Biotech ETFs That Could Double Your Money by 2025 With Zero Effort
In a sector where picking individual stocks is a high-risk, high-reward strategy, the diversification of exchange-traded funds can be highly appealing. 
Via The Motley Fool
Analyzing SPDR Series Trust SPDR S&amp;P Biotech ETF's Unusual Options Activity
SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) shares experienced unusual options activity on Friday. The stock price moved up to $136.19 following the option alert.... 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.